Dimerix Limited

Equities

DXB

AU000000DXB7

Biotechnology & Medical Research

Market Closed - Australian S.E. 01:10:10 2024-03-28 am EDT 5-day change 1st Jan Change
0.3 AUD -1.64% Intraday chart for Dimerix Limited -7.69% +46.34%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Dimerix Raises AU$20 Million for Kidney Disease Study MT
Dimerix Expanding Kidney Drug Study After DMX-200 Performs Better than Placebo MT
Dimerix Limited Reports Earnings Results for the Half Year Ended December 31, 2023 CI
Dimerix Limited Announces Appointment of Mark Diamond as Director CI
Dimerix Secures Investigational New Drug Approval for Kidney Disease Medication in China; Shares Rally 11% MT
Dimerix Appoints Nonexecutive Chair MT
Dimerix Receives AU$10.7 Million Upfront Payment for Commercialization Rights MT
Dimerix Appoints Medical Chief MT
Dimerix Limited Announces Appointment of Dr David Fuller as Chief Medical Officer CI
Softer US Employment Data End Australian Shares' Three-Day Losing Streak MT
Dimerix Surges 154% After Securing License Deal for Kidney Disease Drug MT
Dimerix Secures Conditional US FDA Clearance for Kidney Medication Brand Name MT
Dimerix Secures Regulatory Nod to Conduct Kidney Disease Drug Trial in Malaysia MT
Dimerix Secures AU$9 Million R&D Tax Rebate; Shares Rise 3% MT
Dimerix Limited Reports Earnings Results for the Full Year Ended June 30, 2023 CI
Dimerix Secures Approval for Pediatric Kidney Disease Plan in Europe MT
Dimerix Secures Study Design Approval in China for Phase Three Kidney Disease Trial; Shares Rise 6% MT
Dimerix Raising AU$12 Million to Continue Clinical Program; Shares Down 7% MT
Dimerix Limited Appoints Clinton Snow New Non-Executive Director to the Board, Effective 01 May 2023 CI
Dimerix Limited Reports Earnings Results for the Half Year Ended December 31, 2022 CI
Dimerix Secures AU$2.8 Million in Prepayment of R&D Tax Rebate; Shares Rise 8% MT
Dimerix Secures Safety Approval for Phase 3 Kidney Drug Trial MT
Dimerix Limited Announces Successful Completion of DSMB Review of Phase 3 FSGS Trial CI
US FDA Confirms Inclusion of Adolescent Children in Dimerix's Trial for Kidney Disease Treatment MT
Dimerix Limited Announces That FDA Confirms Inclusion of Paediatrics in Action3 Study of DMX-200 for FSGS CI
Chart Dimerix Limited
More charts
Dimerix Limited is an Australia-based clinical-stage biopharmaceutical company. The Company is focused on developing new therapies in areas with unmet medical needs for global markets. It is focused on developing its products, DMX-200, for Focal Segmental Glomerulosclerosis (FSGS), respiratory complications associated with COVID-19 and Diabetic Kidney Disease and is developing DMX-700 for Chronic Obstructive Pulmonary Disease (COPD). Its DMX-200 and DMX-700 are identified using its assay, Receptor Heteromer Investigation Technology (Receptor-HIT), which is a scalable and globally applicable technology platform enabling the understanding of receptor interactions to rapidly screen and identify new drug opportunities. Its products target multiple global territories, with the initial focus predominantly on the United States and European markets. It has completed two Phase 2 studies: one in FSGS and one in diabetic kidney disease. Receptor-HIT is licensed to Excellerate Bioscience.
More about the company
  1. Stock
  2. Equities
  3. Stock Dimerix Limited - Australian S.E.
  4. News Dimerix Limited
  5. Dimerix : Expands Phase 3 Study for COVID-19 Drug to Australia; Shares Rise 4%